Durect  Corporation (DRRX) announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States DURECT's POSIMIR® ...

Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, will host its 2026 capital markets day for investors and analysts: Tuesday, 8 September 13:30-17:00 UK time London ...

Novartis spinout Sandoz garnered $2.6 billion in second-quarter product sales. After the performance, the company raised its sales guidance for the year. (Photo by Sebastian Kahnert/picture alliance ...

(Reuters) -Sandoz shares dipped on their market debut on Wednesday after the generic and biosimilar drugmaker was valued at a lower-than-expected 10.3 billion Swiss francs ($11.2 billion) in its ...

Sandoz bought the Cimerli (ranibizumab-eqrn) business from Coherus Biosciences, the companies announced Monday morning. In January, Sandoz and Coherus entered into an agreement on a $170 million cash ...

Switzerland-based Sandoz , a leader in affordable medicines, today inaugurated a new biosimilar development center in ...

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

At an Extraordinary General Meeting, Novartis AG's (NYSE:NVS) shareholders approved the proposed 100% spin-off of Sandoz. Novartis shareholders and Novartis ADR holders will receive one Sandoz share ...

Generic versions of Emergent's Narcan have been priced higher than expected, Cantor Fitzgerald analysts say, which is a positive for the durability of Narcan’s sales. Sandoz and Teva launched generics ...

The Swiss drugmaker announced intentions to spin off the Sandoz business in August, offering stakeholders one Sandoz share for every five Novartis shares via a dividend-in-kind distribution. Novartis ...

Sandoz has started construction for a new, state-of-the-art biosimilars production center for sterile product manufacturing in Brnik, Slovenia. This $440 million project brings the company’s total ...

Sandoz has signed a global collaboration agreement with Shanghai Henlius Biotech to commercialize a biosimilar of oncology therapy, ipilimumab (Bristol-Myers Squibb’s Yervoy). The agreement is for a ...